A Phase 2 interventional study of Omalizumab in Food Hypersensitivity, sponsored by Johns Hopkins University. Recruiting at 1 site in United States. Open to participants aged 1 Year to 55 Years. Per ClinicalTrials.gov, last updated 2026-06-08.
Sponsored by Johns Hopkins University · Phase 2, Interventional, and Treatment
How we know · 3 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing omalizumab in Food Hypersensitivity — 4 open to participants now, 4 under way, none of them phase 3. Omalizumab · Food Hypersensitivity.
Among the 12 studies testing omalizumab in Food Hypersensitivity, this one is the 7th largest by planned enrollment, is one of 2 that started in 2025, is one of 5 in phase 2, and was the 11th registered.
378 studies on the registry are indexed under Food Hypersensitivity; 90 are open to participants now.
Browse Food Hypersensitivity studies →4 of the 12 studies testing omalizumab in Food Hypersensitivity are open now, in 1 country. Recruiting first, the newest first:
Johns Hopkins University · Sites in United States
Ages 1–30
Massachusetts General Hospital · Sites in United States
Ages 1–55
National Jewish Health · Sites in United States
Ages 1–55 · Healthy volunteers
By country, each count listing its studies:
Omalizumab: first FDA approval 2003 (XOLAIR), first EMA approval 2005. What it is approved for, and how studies give it, is on its page →
Of the 53 Food Hypersensitivity studies recruiting now, 8 (15%) set no upper age limit and 41 (77%) stop at 75 or younger; 45 take children under 18; 17 take healthy volunteers.
This study: 1 Year to 55 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, omalizumab is the treatment under test here. Read study by study →
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 7 · Phase 4 5
First in 2009; this study’s year is marked. 2 started in 2025.
This study's planned enrollment of 32 is below the median of 60 across 248 interventional studies indexed under Food Hypersensitivity.
Median enrollment 34 across the 12 interventional studies. Of the 8 that completed or were terminated, 5 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 12 has an industry lead sponsor. The 8 most frequent:
Johns Hopkins University is the lead sponsor of 1,817 studies on the registry; 316 are open to participants now.
Of its 208 completed or terminated interventional studies of FDA-regulated products, 144 (69%) have results posted.
11 studies in Food Hypersensitivity by Johns Hopkins University: 2 open now, 2 under way, none of them phase 3. Of 8 finished, 8 (100%) have results posted.
Among the 11 studies in Food Hypersensitivity by Johns Hopkins University, this one is the 3rd largest by planned enrollment, is the only one that started in 2025, is one of 5 in phase 2, and was the 10th registered.
Johns Hopkins University’s Food Hypersensitivity studies by the year they started, since 2006.
2 of the studies testing omalizumab in Food Hypersensitivity that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06934200Johns Hopkins UniversityOmalizumab for the Treatment of Food Allergy in Patients With Elevated Total IgE Levels | 2027-04-15 |
| NCT06943534Massachusetts General HospitalOmalizumab Weight-Based Dosing Efficacy Trial | 2027-05-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 12 studies testing omalizumab in Food Hypersensitivity, from their registry updates:
Among Johns Hopkins University’s 11 in Food Hypersensitivity:
This tab as a report to print or save as PDF → With an account.
In this project, the investigators would like to learn if 24 weeks (about 5 and a half months) of omalizumab injections, given every 2 weeks, will be safe and effective for food allergic people who have a total immunoglobulin E (IgE) above the current FDA approved dosing regimen enabling a person to increase tolerance to the food(s) that the person is allergic to.
The investigators would also like to learn if participants who demonstrate increased tolerance to food after 24 weeks of omalizumab, can introduce the food into the diet utilizing an additional 8 weeks (about 2 months) of twice weekly omalizumab injections.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This is an open label study of omalizumab with no placebo. Participants who meet study inclusion criteria and are enrolled in the study will receive omalizumab. The dose of omalizumab will be based on participant's weight.
Drug: Omalizumab
omalizumab injections
Number of participants without dose limiting symptoms
Consumption of a single dose of 600mg or more of food protein without dose-limiting symptoms during the week 24 Double-blind, Placebo-controlled, Food Challenge
Time frame: 24 weeks
Plan to share: No
Started May 2025 (actual). Primary completion is estimated for Apr 2027, 22 months after the start.
Of 19 phase 2 interventional studies under Food Hypersensitivity, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 71. This study's planned 22 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Omalizumab